We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Johnson and Johnson | NYSE:JNJ | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.38 | 0.26% | 147.20 | 2,137 | 10:55:25 |
From Apr 2021 to Apr 2024
By Colin Kellaher
Johnson & Johnson's Janssen Pharmaceutical Cos. unit on Tuesday said the European Commission approved the company's Byannli six-month maintenance treatment for schizophrenia in adults.
The drugmaker said the approval, which covers patients who are clinically stable on monthly or three-month doses, makes Byannli the first twice-yearly treatment of schizophrenia in adults in Europe.
The U.S. Food and Drug Administration in September approved a six-month version of the antipsychotic, marketed in the U.S. as Invega.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
November 23, 2021 07:03 ET (12:03 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Johnson and Johnson Chart |
1 Month Johnson and Johnson Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
